Topical long-term therapy of @entity1569 with @entity560    analogues, XXXX and their two compound formulations: position paper on evidence and use in daily practice.

@entity1 @entity1569 @entity3875 @entity11885 @entity5935 @entity2116 @entity560 @entity288
BACKGROUND: Current data from daily practice show that @entity560    analogues, @entity288 and their fixed combination products are used heterogeneously for topical long-term treatment of @entity1569 . AIM: To evaluate scientific evidence about topical long-term therapy with @entity3875 analogues, @entity288 and their two-compound-products in @entity1569 and @entity11885 and to develop daily practice recommendations. METHODS: Systematic literature review via PubMed and Embase and informal expert consensus. RESULTS: The search strategy identified 21 relevant clinical trials. Best evidence regarding topical long term treatment was available for the two-compound-formulation containing @entity2116 and @entity5935 . In a comparative trial in @entity1569 the two-compound-formulation showed superior tolerability and cost effectiveness compared to monotherapy. In @entity11885 the two-compound-gel was superior compared to @entity2116 monotherapy. Standardized and simplified treatment application modes resulted in a better clinical outcome comparing to on-demand therapies. DAILY PRACTICE RECOMMENDATIONS: @entity1 should be proactively involved in the choice of treatment, formulation and mode of application. Besides long-term treatment with the two-compound-formulation other treatment regimens including @entity2116 monotherapy can also be considered. Due to a favorable risk-benefit ratio in maintenance trials and due to better cost-effectiveness the application of two-compound-products once or twice a week after initial therapy is recommended.
